SEPTInvestingStart Free

ABUS SCHEDULE 13D/A: Activist campaign

Roivant Sciences

Filed with the SEC on · accession 0001140361-26-038693

ABUS filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Oct 5, 2026. Roivant Sciences filed an amended Schedule 13D disclosing the names and occupations of its board members as covered persons in connection with its stake in Arbutus Biopharma. The stock moved +4.5% by the first close after the filing.

Summary of the filing

Roivant Sciences filed an amended Schedule 13D disclosing the names and occupations of its board members as covered persons in connection with its stake in Arbutus Biopharma. The filing indicates Roivant's continued activist involvement with the company.

For details, click here →

Key details

Filer/activist investorRoivant Sciences Ltd.
Subject companyArbutus Biopharma Corp
Affiliated entityQVT Financial LP
Employer of covered personTenpoint Therapeutics, Ltd.
Employer of covered personTenet Healthcare
Affiliated entityK2HealthVentures
Employer of covered personPatient Square Capital
Employer of covered personDexcel Pharma
Director and principal executive officer, roivant sciences ltd.; ceo, roivant sciences, inc.Matthew Gline
Partner and head of life sciences, qvt financial lpKeith Manchester
Cfo, tenpoint therapeutics, ltd.Melissa Epperly
Founder and ceo, qvt financial lpDaniel Gold
Director, tenet healthcare; founder, k2healthventuresMeghan FitzGerald
Managing partner, patient square capitalJames C. Momtazee
Co-ceo, dexcel pharmaIlan Oren
Director, roivant sciences ltd.; president and cio, roivant sciences, inc.Mayukh Sukhatme

How ABUS stock reacted

Close before

$4.47

Oct 2, 2026

First close after

+4.47%

$4.67

5 trading days

-5.59%

$4.22

Since filing

-18.23%

$3.65

✦ Ask GOAX AI about this filing — what it means for ABUS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ABUS?

Click here

Frequently asked questions

What did ABUS file with the SEC on Oct 5, 2026?

ABUS filed a SCHEDULE 13D/A (Activist campaign). Roivant Sciences filed an amended Schedule 13D disclosing the names and occupations of its board members as covered persons in connection with its stake in Arbutus Biopharma. The filing indicates Roivant's continued activist involvement with the company.

What does a activist campaign mean for ABUS stock?

A settlement removes uncertainty; the stock often reacts to whether the amount is bigger or smaller than investors expected.

How do I read a SCHEDULE 13D/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).

How did ABUS stock react to this filing?

ABUS closed at $4.47 before the filing and $4.67 on Oct 5, 2026 (+4.47%). Five trading days later: $4.22 (-5.59%).

Other ABUS SEC filings

Get alerts when ABUS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ABUS overviewABUS analysisABUS newsLatest SEC filings